Vaxcyte, Inc. PCVX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$946.53M-85.7% | -$766.63M-65.2% | -$657.2M-29.5% | -$547.5M-10.1% | -$509.63M-16.7% | ||
| $16.39M+82.9% | $16.4M+134% | $11.76M+134% | $10.49M+159% | $8.96M+160% | ||
| $146.19M+49.5% | $138.85M+63.7% | $127.22M+72.4% | $113.18M+72.1% | $97.81M+72.4% | ||
| —— | —— | —— | —— | -$251K-102% | ||
| —— | —— | —— | —— | —— | ||
| $24.96M— | $17.72M— | $11.46M— | $12.03M— | —— | ||
| $9.45M+9.1% | $8.46M-4.3% | $8.08M-10.0% | $8.65M+8.8% | $8.67M+15.9% | ||
| —— | —— | —— | —— | $59.69M+796% | ||
| -$769.93M-67.5% | -$655.58M-44.8% | -$542.15M-15.3% | -$459.55M+1.6% | -$459.78M-12.6% | ||
| $10.4M-53.1% | $13.71M-38.9% | $15.08M-36.3% | $16.2M-37.8% | $22.17M— | ||
| $1.48B-45.4% | $1.21B-60.8% | $1.73B-29.9% | $2.71B+86.8% | $2.71B+76.9% | ||
| $173.51M+100% | $174.69M+161% | $130.99M+183% | $119.16M+357% | $86.65M+386% | ||
| $80.63M+106% | $437.35M+122% | -$234.94M+83.9% | -$1.27B-133% | -$1.43B-79.2% | ||
| $15.99M-92.1% | $13.01M-93.4% | $9.59M— | $98.74M— | $202.02M— | ||
| $15M-7.9% | $10.99M-23.1% | $11.07M-21.9% | $16.43M+183% | $16.28M+162% | ||
| $602.84M-63.0% | $2.01M-99.9% | $4.51M-99.8% | $1.52B+55.5% | $1.63B+15.2% | ||
| $603K— | $2.44M— | $3.61M— | -$2.25M— | —— | ||
| -$85.86M+67.5% | -$213.77M-2,184% | -$768.96M-252% | -$211.71M— | -$264.45M— | ||
| $12.63M-61.3% | $14.43M-62.7% | $23.35M-20.6% | $27.19M-28.2% | $32.63M-18.0% | ||
| $25.95M+988% | $34.77M+922% | $22.43M+248% | $28.09M— | $2.39M— | ||
| —— | —— | —— | —— | $3.07M+154% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $59.69M+796% | ||
| —— | —— | —— | —— | $67.52M+438% | ||
| $50.21M+105% | $39.89M+50.5% | $32.81M-41.9% | $28.42M-42.3% | $24.48M-42.0% | ||
| $24.96M— | $17.72M— | $11.46M— | $12.03M— | —— | ||
| $9.45M+9.1% | $8.46M-4.3% | $8.08M-10.0% | $8.65M+8.8% | $8.67M+15.9% | ||
| $34.62M-69.0% | $43.26M-55.3% | $63.5M-24.1% | $88.41M+39.2% | $111.67M+147% | ||
| $1.43B+7.8% | $1.53B+35.1% | $1.45B+30.0% | $1.42B+39.9% | $1.33B+63.3% | ||
| $173.51M+100% | $174.69M+161% | $130.99M+183% | $119.16M+357% | $86.65M+386% | ||
| —— | $0-100% | $559.93M-69.2% | $1.12B-19.6% | $1.68B+73.4% | ||
| —— | —— | —— | —— | —— | ||
| $15.99M— | $13.01M— | $15.57M— | $27.01M— | —— | ||
| $10.41M— | $7.96M— | $13.64M— | $11.79M— | —— | ||
| —— | —— | —— | —— | $59.69M+796% | ||
| -$780.32M-61.9% | -$669.29M-40.9% | -$557.23M-12.9% | -$475.75M+3.5% | -$481.95M-13.6% | ||
| -$780.32M-61.9% | -$669.29M-40.9% | -$557.23M-12.9% | -$475.75M+3.5% | -$481.95M-13.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Vaxcyte, Inc. generate?
- Vaxcyte, Inc. (PCVX) generated -$769.9M in operating cash flow over the trailing twelve months.
- What is Vaxcyte, Inc.'s free cash flow?
- After $10.4M of capital expenditures, Vaxcyte, Inc.'s free cash flow was -$780.3M over the trailing twelve months, down 61.9% year over year.
- Where does Vaxcyte, Inc.'s cash flow data come from?
- Every line is extracted from Vaxcyte, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.